Regeneron Reports meta-analysis Data for Funapide in Juvenile idiopathic arthritis

Regeneron today announced meta-analysis results for Funapide in patients with Juvenile idiopathic arthritis. The study demonstrated that Funapide demonstrates durable complete remissions compared to standard of care or placebo. These results provide important insights into the treatment of Juvenile idiopathic arthritis and support the continued development of Funapide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Funapide was consistent with previous observations, with no new safety signals identified.